In December 2023, The FDA granted approval for the first gene therapies to treat a genetic blood disorder characterized by abnormal hemoglobin production. Which disease did the FDA approve these therapies for?

A. Multiple Sclerosis
B. Sickle Cell Disease
C. Cystic Fibroses
D. Parkinson’s Disease

Answer

Correct Answer: B. Sickle Cell Disease

Detail about MCQs

In December 2023, The FDA granted approval for the first gene therapies to treat a genetic blood disorder “Sickle Cell Disease” characterized by abnormal hemoglobin production.

Write a Comment

Your email address will not be published. Required fields are marked *